Bright Minds Biosciences Debt-to-Equity Ratio Growth & History (DRUG)

Bright Minds Biosciences's debt-to-equity ratio was 0.00 for fiscal 2025.

View full Bright Minds Biosciences company overview

Bright Minds Biosciences annual debt-to-equity ratio history

Bright Minds Biosciences annual debt-to-equity ratio

Fiscal yearPeriod endedDebt-to-equity ratioChangeGrowth
20252025-09-300.00−0.02−92.87%
20242024-09-300.020.01+92.76%
20232023-09-300.01−0.00−16.01%
20222022-09-300.010.01
20212021-09-300.00

Bright Minds Biosciences debt-to-equity ratio trends

Between the periods ended 2021-09-30 and 2025-09-30, Bright Minds Biosciences's debt-to-equity ratio increased from 0.00 to 0.00, a change of 0.00. The latest reported quarter, Q3 2026, shows 0.00.

About the metric

What the debt-to-equity ratio means

The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.

Calculation and source

How debt-to-equity is calculated

TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Bright Minds Biosciences source filings ↗

Community posts

It’s quiet here.

No posts about DRUG yet. Start the conversation.

Write the first post